Evidence map›Paper›PMID 37170124›Full record

ArticleJournal of experimental & clinical cancer research : CR2023

CRISPR/Cas9-based genome-wide screening of the deubiquitinase subfamily identifies USP3 as a protein stabilizer of REST blocking neuronal differentiation and promotes neuroblastoma tumorigenesis.

Janardhan Keshav Karapurkar, Min-Seong Kim, Jencia Carminha Colaco, Bharathi Suresh, Neha Sarodaya, Dong-Ho Kim, Chang-Hwan Park, Seok-Ho Hong, Kye-Seong Kim, Suresh Ramakrishna

Open access · goldAbstract read
In one paragraph

Article in Journal of experimental & clinical cancer research : CR, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
2.7field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Targeting USP11 counteractsTheranostics · 2025
    Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Janardhan Keshav Karapurkar *Graduate School of Biomedical Science and Engineering, Hanyang University, Seoul, 04763, South Korea.
Min-Seong Kim *Graduate School of Biomedical Science and Engineering, Hanyang University, Seoul, 04763, South Korea.
Jencia Carminha ColacoGraduate School of Biomedical Science and Engineering, Hanyang University, Seoul, 04763, South Korea.
Bharathi SureshGraduate School of Biomedical Science and Engineering, Hanyang University, Seoul, 04763, South Korea.
Neha SarodayaGraduate School of Biomedical Science and Engineering, Hanyang University, Seoul, 04763, South Korea.
Dong-Ho KimGraduate School of Biomedical Science and Engineering, Hanyang University, Seoul, 04763, South Korea.
Chang-Hwan ParkGraduate School of Biomedical Science and Engineering, Hanyang University, Seoul, 04763, South Korea.
Seok-Ho HongDepartment of Internal Medicine, School of Medicine, Kangwon National University, Chuncheon, South Korea.
Kye-Seong KimGraduate School of Biomedical Science and Engineering, Hanyang University, Seoul, 04763, South Korea. ks66kim@hanyang.ac.kr.
Suresh RamakrishnaGraduate School of Biomedical Science and Engineering, Hanyang University, Seoul, 04763, South Korea. suri28@hanyang.ac.kr.ORCID http://orcid.org/0000-0002-4038-1085
Hanyang University · KRKangwon National University · KR

Funding

Ministry of Science and ICT, South Korea 2017R1A5A2015395Ministry of Science and ICT, South Korea 2022M3A9E4016936Ministry of Science and ICT, South Korea 2022M3A9E4082648Ministry of Science and ICT, South Korea 22A0304L1-01National Research Foundation of Korea 2021M3A9H3015389
6 · The paper itself

Abstract

backgroundThe repressor element-1 silencing transcription factor (REST), a master transcriptional repressor, is essential for maintenance, self-renewal, and differentiation in neuroblastoma. An elevated expression of REST is associated with impaired neuronal differentiation, which results in aggressive neuroblastoma formation. E3 ligases are known to regulate REST protein abundance through the 26 S proteasomal degradation pathway in neuroblastoma. However, deubiquitinating enzymes (DUBs), which counteract the function of E3 ligase-mediated REST protein degradation and their impact on neuroblastoma tumorigenesis have remained unexplored.

methodsWe employed a CRISPR/Cas9 system to perform a genome-wide knockout of ubiquitin-specific proteases (USPs) and used western blot analysis to screen for DUBs that regulate REST protein abundance. The interaction between USP3 and REST was confirmed by immunoprecipitation and Duolink in situ proximity assays. The deubiquitinating effect of USP3 on REST protein degradation, half-life, and neuronal differentiation was validated by immunoprecipitation, in vitro deubiquitination, protein-turnover, and immunostaining assays. The correlation between USP3 and REST expression was assessed using patient neuroblastoma datasets. The USP3 gene knockout in neuroblastoma cells was performed using CRISPR/Cas9, and the clinical relevance of USP3 regulating REST-mediated neuroblastoma tumorigenesis was confirmed by in vitro and in vivo oncogenic experiments.

resultsWe identified a deubiquitinase USP3 that interacts with, stabilizes, and increases the half-life of REST protein by counteracting its ubiquitination in neuroblastoma. An in silico analysis showed a correlation between USP3 and REST in multiple neuroblastoma cell lines and identified USP3 as a prognostic marker for overall survival in neuroblastoma patients. Silencing of USP3 led to a decreased self-renewal capacity and promoted retinoic acid-induced differentiation in neuroblastoma. A loss of USP3 led to attenuation of REST-mediated neuroblastoma tumorigenesis in a mouse xenograft model.

conclusionThe findings of this study indicate that USP3 is a critical factor that blocks neuronal differentiation, which can lead to neuroblastoma. We envision that targeting USP3 in neuroblastoma tumors might provide an effective therapeutic differentiation strategy for improved survival rates of neuroblastoma patients.

Indexed as

NeuroblastomaTranscription FactorsAnimalsCell DifferentiationCell Transformation, NeoplasticCRISPR-Cas SystemsHumansMiceNeuronsUbiquitinationUbiquitin-Protein LigasesUbiquitin-Specific ProteasesTranscription FactorsUbiquitin-Protein LigasesUbiquitin-Specific ProteasesUSP3 protein, humanNeuronal tumorsPrognostic markerProtein stabilizationProtein turn-overRA-induced differentiationUbiquitinationUbiquitin-specific protease

Identifiers

PMID37170124
PMCPMC10176696
OpenAlexW4376224940

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.